ACM
KPTI icon

ADAR1 Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

ADAR1 Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
+205,200
New +$1.56M 0.07% 147

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

ADAR1 Capital Management's KPTI Position: Q1 2026 in Review

ADAR1 Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 173% in Q1 2026, buying an estimated $661K and bringing the position to 136,736 shares worth $762K. The position accounts for 0.04% of the portfolio, ranked #182.

ADAR1 Capital Management first reported a position in KPTI in Q1 2024 and has held it in 5 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • ADAR1 Capital Management held 136,736 shares of Karyopharm Therapeutics worth $762K as of Q1 2026.
  • ADAR1 Capital Management bought 86,736 Karyopharm Therapeutics shares in Q1 2026, an estimated $661K.
  • Karyopharm Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q1 2026, its #182 holding.
  • ADAR1 Capital Management first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.